HudsonLD. Causes of the adult respiratory distress syndrome: Clinical recognition. In: BoneRC, editor. The adult respiratory distress syndrome. Clin Chest Med1982;3(1):195–212.
2.
MurrayJF. Mechanisms of acute respiratory failure. Am Rev Respir Dis1977;115:1071–1078.
3.
PettyTL. Adult respiratory distress syndrome: Defi-nition and historical perspective. In: BoneRC, editor. The adult respiratory distress syndrome. Clin Chest Med1982;3(1):3–7.
4.
PontoppidanH, GeffinB, LowensteinE.Acute res-piratory failure in the adult (first of three parts). N Engl J Med1972;287:690–698.
5.
ShimadaY, YoshiyaI, TonakaK, . Evaluation of the progress and prognosis of adult respiratory dis-tress syndrome: Simple respiratory physiologic measurements. Chest1979;76:180–186.
6.
BlakeLH. Goals and progress of the National Heart and Lung Institute collaborative membrane oxygen-ation study. In: ZapelWM, QvistJ, editors. Artificial lungs for acute respiratory failure: Theory and prac-tice. New York: Academic Press; 1976.
7.
FowlerAA, HammonRF, GoodJT, . Risk with common predispositions. Ann Intern Med1982;98:595–597.
8.
PepePE, PotkinRT, HoltmanDH, . Clinical predictors of the adult respiratory distress syndrome. Am J Surg1982;144:124–130.
9.
WhiteMK, SheproD, HechtmanB.Pulmonary function and platelet-lung interaction. J Appl Phys-iol1973;34:697–703.
10.
RadegranL, BergentzSE, LewisDH, . Pulmo-nary effects of induced platelet aggregation. Intra-vascular obstruction or vasoconstriction. Scand J Clin Lab Invest1971;28:423–427.
11.
EvansG, MustardJF. Inhibition of the platelet-sur-face reaction in endotoxin shock and the generalized Schwartzman reaction. J Clin Invest1968;47:31a.
12.
SteinM, ThomasDP. Role of platelets in the acute pulmonary responses to endotoxin. J Appl Physiol1967;23:47–52.
13.
BrighamKL. Mechanisms of lung injury. In: BoneRC, editor. The adult respiratory distress syndrome. Clin Chest Med1982;3(1):9–24.
14.
DemlingRH. The pathogenesis of respiratory failure after trauma and sepsis. Surg Clin North Am1980;60(6):1373–1390.
15.
HohnDC, MeyersAJ, GherineST, . Production of acute pulmonary injury by leukocytes and acti-vated complement. Surgery1980;88:49–57.
16.
HymanA, SponnhaleE, KadowitzP.Prostaglandins and the lung. In: Lung disease: State of the art 1977-1978. New York: American Lung Association; 1978:229–254.
BoneRC, FrancisPB, PierceAK. Intravascular co-agulation associated with the adult respiratory dis-tress syndrome. Am J Med1976;61:585–590.
19.
Van DorpDA. Aspects of the biosynthesis of pros-taglandins. Prog Biochem Pharmacol1967;3:71–82.
20.
SamuelssonB.Biosynthesis and metabolism of pros-taglandins. Biochem Pharmacol1967;3:59–70.
21.
RamwellRW, ShawJE. Biological significance of the prostaglandins. Recent Prog Horm Res1970;26:139–187.
22.
BertstromS, DresslerF, KrabischL, . The iso-lation and structure of a smooth muscle stimulating factor in normal sheep and pig lungs: Prostaglandin and related factors. Arkh Kemi1962;12:63–66.
23.
AnggardE.The isolation and determination of pros-taglandins in lungs of sheep, guinea pig, monkey and man. Biochem Pharmacol1965;14:1507–1516.
24.
MatheAA. Studies on actions of prostaglandins in the lung. Acta Physiol Scand1976;441:1–55.
25.
CuthbertMF. Prostaglandins and respiratory smooth muscle. In: CuthbertMF, editor. The prosta-glandins. Philadelphia: JB Lippincott; 1973:253–285.
26.
SamuelssonB, FranstromE, GreenK, . Metab-olism of prostaglandins. Ann NY Acad Sci1971;180:138–161.
27.
KadowitzPJ, JoinerPD, HymanAL. Physiological and pharmacological roles of prostaglandins. Am Pharm1975;15:285–305.
28.
LeslieCA, LevineL.Evidence for the presence of a prostaglandin E2-9-keto reductase in rat organs. Biochem Biophys Res Commun1973;52:717–724.
29.
ZurierRB. Mediators of inflammation. In: WeissmanG, editor. Mediators of inflammation. New York: Plenum Press; 1974:163.
30.
WaldkerJR, SmithMJH, Ford-HutchinsonAW. Prostaglandins and leukotaxis. J Pharm Pharmacol1976;28:745–747.
31.
FletcherJR, RamwellPW. Prostaglandins in shock: To give or to block. Adv Shock Res1980;3:57–66.
32.
FletcherJR, RamwellPW, HarrisRH. Thrombox-ane, prostacyclin and hemodynamic events in pri-mate endotoxin shock. Adv Shock Res1980;3:145–148.
33.
WiseWC, CookJA, HalushkaPV. Implications for thromboxane A2 in the pathogenesis of endotoxic shock. Adv Shock Res1981;6:83–91.
34.
WebbPJ, WestwickJ, ScullyMF, . Do prosta-cyclin and thromboxane play a role in endotoxic shock?Br J Surg1981;68:720–724.
35.
BowersRE, EllisEF, BrighamKL, . Effects of prostaglandin cyclic endoperoxides on the lung cir-culation of unanesthetized sheep. J Clin Invest1979;63:131–137.
36.
DemlingRH, SmithM, GuntherR, . The effect of prostacyclin infusion on endotoxin-induced lung injury. Surgery1981;89(2):257–263.
37.
DemlingRH, SmithM, GuntherR, . Pulmonary injury and prostaglandin production during endo-toxemia in conscious sheep. Am J Physiol1981;240:H348–H353.
38.
TrakerDL, AdairTH, AdamsTJr. Hemodynamic consequences of endotoxemia in sheep. Circ Shock1981;8:551–561.
39.
MarxJL. The leukotrienes in allergy and inflam-mation. Science1982;215:1380–1383.
40.
SamuelssonB, BorgeotP, HammarstromH, . Leu-kotrienes: A new group of biologically acting com-pounds. Adv Prostaglandin Thromboxane Res1980;6:1–17.
41.
ChandN.FPL 55712—an antagonist of slow react-ing substance of anaphylaxis (SRS-A): A review. Agents Actions1979;9:133–140.
42.
WeisoJW, DrazenJM, ColesN.Bronchoconstrictor effects of leukotriene C in humans. Science1982;216:196–198.
43.
BrocklehurstWE. Slow-reacting substance and re-lated compounds. Prog Allergy1962;6:539–558.
44.
WassermanSI, GoetzlEJ, AustenKF. Inactivation of slow-reacting substance of anaphylaxis by human eosinophil arylsulfatase. J Immunol1975;114:645–649.
45.
BrocklehurstWE. The release of histamine and for-mation of a slow-reacting substance (SRS-A) during anaphylactic shock. J Physiol1960;151:416–435.
46.
OrangeRP, StechschulteDJ, AustenKF. Cellular mechanisms involved in the release of slow-reacting substance of anaphylaxis. Fed Proc1969;28:1710–1715.
47.
SpectorWG, WilloughbyDA. The pharmacology of inflammation. New York: Grune and Stratton; 1968.
48.
SmithM, GuntherR, ZaiacC, . Pulmonary mi-crovascular injury from lipoxygenase infusion: Comparison with endotoxemia. Circ Shock1981;8:647–652.
49.
BrighamK, BowersR, McKeonC.Methylpredni-solone prevention of increased lung vascular perme-ability following endotoxemia in sheep. J Clin Invest1981;67:1103–1108.
50.
MaronMB. Differential effects of histamine on pro-tein permeability in dog lung and forelimb. Am J Physiol1982;242:H565.
51.
BrighamK.Effects of histamine on lung transvas-cular fluid and protein movement in awake sheep. Chest1975;67:508.
52.
BoneRC, LernerS, MurphyEM, . Vasoactive medication in the pathogenesis of experimental adult respiratory distress syndrome. Chest1979;75:218–220.
53.
LemaireI, TsengR, LemaireS.Systemic adminis-tration of β-endorphin: Potent hypotensive effect in-volving a serotonergic pathway. Proc Natl Acad Sci USA1978;75:6240–6242.
54.
HoladayJW, FadenAI. Naloxone reversal of endo-toxin hypotension suggests role of endorphins in shock. Nature1978;275:450–451.
55.
FadenAI, HoladayJW. Experimental endotoxin shock: The pathophysiologic function of endorphins and treatment with opiate antagonists. J Infect Dis1980;142:229–237.
56.
JanssenHF, LuthererLO. Ventriculocisternal administration of naloxone protects against severe hypotension during endotoxin shock. Brain Res1980;194:608–612.
57.
ReynoldsDG, GurllNJ, VargishT, . Blockade of opiate receptors with naloxone improves survival and cardiac performance of canine endotoxic shock. Circ Shock1980;7:38–49.
58.
PetersWP, JohnsonMW, FriedmanPA, . Pres-sor effect of naloxone in septic shock. Lancet1981;1:529–532.
59.
BoneRC, JacobsER, PotterDM, . Endorphins in endotoxin shock. Microcirc1981;1(3):285–295.
60.
HensonPM, CochraneCG. The effect of comple-ment depletion on experimental tissue injury. Ann NY Acad Sci1975;256:426–440.
61.
CochraneCG, VannueER, DixonFJ. A role of poly-morphonuclear leukocytes and complement in neu-trotoxic nephritis. S Exp Med1965;112:99–116.
62.
da SilvaWD, EiseleJW, LepowIH. Complement as a mediator of inflammation. J Exp Med1967;126:1027–1084.
CraddockPR, FrehrJ, BrighamKL, . Comple-ment and leukocyte-mediated pulmonary dysfunc-tion in hemodialysis. N Engl J Med1977;296:769–774.
65.
AndrewsBS, ShadforthN, CunninghamP, DavisJSIV. Demonstration of a Clq receptor on the surface of human endothelial cells. J Immunol1981;127:1075.
66.
WebsterRO, LarsenGL, MitchellBC, . Absence of inflammatory lung injury in rabbits challenged in-travascularly with complement-derived chemotactic factors. Am Rev Respir Dis1982;125:335.
67.
JosePJ, ForrestMJ, WilliamsTJ. Human C5a des Arg increases vascular permeability. J Immunol1981;127:2376.
68.
JohnsonA, MalikAB. Effect of granulocytopenia on extravascular lung water content after microembo-lization. Am Rev Respir Dis1980;122:561–568.
69.
WalkerRI, FletcherJR. Possible contribution of platelets to the pathophysiological effects of endo-toxins at the cellular level. In: Pathophysiological ef-fects of endotoxins at the cellular level. New York: Alan R Liss Inc; 1981:173–185.
70.
VaageJ.The role of platelets in posttraumatic pul-monary insufficiency. Acta Chem Scand (Suppl)1980;499:141–158.
71.
MurphyTL, AllisonRC, WeismanIM, . Role of platelet serotonin in the canine pulmonary response to endotoxin. J Appl Physiol1981;50:178–184.
72.
PackhamNA, NishizawaEE, MustardJF. Response of platelets to tissue injury. Biochem Pharmacol1968;17:84.
73.
WekslerBB, CoupalE.Platelet-dependent genera-tion of chemotactic activity in serum. J Exp Med1973;137:1419–1430.
74.
HumphreyDM, McManusLM, SataouchiK, . Vasoactive properties of acute glyceryl ether phos-phorcholine and analogues. Lab Invest1982;46:422–428.
75.
MinnaJD, RobboySJ, ColemanRW. Disseminated intravascular coagulation in man. Springfield IL: Charles C Thomas; 1974:26–34.
76.
MerskeyC.Defibrination syndrome. In: BiggsR, editor. Human blood coagulation, haemostasis and throm-bosis. Oxford: Blackwell Scientific Publications; 1976:92–536.
77.
RobboySJ, ColmanRW, MinnaJD. Pathology of disseminated intravascular coagulation (DIC): Analysis of 26 cases. Hum Pathol1972;3:327–340.
78.
LindquistO, RammerL, SaldeenT.Pulmonary insufficiency and fibrinolysis inhibition in posttrau-matic autopsy material. Acta Chir Scand1972;138:545–549.
79.
SchneiderRC, ZapolWM, CarvalhoAC. Platelet consumption and sequestration in severe acute res-piratory failure. Am Rev Respir Dis1980;122:445–451.
CurreriPW, WilterdinME, BaxterCR. Coagulation dynamics following thermal injury. Ann Surg1975;181:161–164.
84.
SatterwhiteTK, HarvigerJ, BruklowSL, . Deg-radation products of fibrinogen and fibrin in bac-teremia due to gram-negative rods. J Infect Dis1973;127:437–442.
85.
CurreriPW, WilterdinkME, BaxterCR. Character-ization of elevated fibrin split products following thermal injury. Ann Surg1975;181:157–161.
86.
HaynesJB, HyersTM, GiclasPC, . Elevated fibrinogen degradation products in adult respiratory distress syndrome. Am Rev Respir Dis1980;122:841–847.
87.
HolcroftJW, BlaisdellFW, TrunkeyDD, . In-travascular coagulation and pulmonary edema in the septic baboon. J Surg Res1977;22:209–220.
88.
MalikAB, HoyteVZ. Time course of pulmonary vascular response to microembolization. J Appl Physiol1977;43:51–58.
89.
ArforsKE, BuschC, JakobsonS, . Pulmonary insufficiency following intravenous infusion of thrombin and AMCA (tranexamic acid) in the dog. Acta Chir Scand1972;138:445–452.
90.
StaubNC, OhkudaK, NakaharaK, . Effects of microemboli on lung fluid balance in anesthetized sheep. Chest (Suppl)1977;71:301–302.
91.
BinderAS, NakaharaK, OhkudaK, . Effect of heparin on fibrinogen depletion on lung fluid bal-ance in sheep after emboli. J Appl Physiol1979;47:213–219.
92.
BinderAS, KagelerW, PerelA, . Effect of platelet depletion on lung vascular permeability after mi-croemboli in sheep. J Appl Physiol1980;48:414–420.
93.
RatnoffOD. The effect of human plasmin upon cu-taneous vascular permeability. Thromb Diast Hae-morrh1966;20:210–215.
94.
BuckoW, de GaetanoG, FrancoR, . Biological properties of dialysable peptides derived from plas-min digestion of bovine fibrinogen preparations. Thromb Haemost1976;35:651–658.
95.
BelewM, GerdinB, LindebergG, . Structure ac-tivity relationships of vasoactive peptides derived from fibrin or fibrinogen degraded by plasmin. Biochem Biophys Acta1980;621:169–178.
96.
GerdinB, SaldeenT.Effect of fibrin degradation products on microvascular permeability. Thromb Res1978;13:995–1006.
97.
BuschC, GerdinB.Effect of low molecular weight fibrin degradation products on endothelial cells in culture. Thromb Res1981;22:33–39.
98.
ManwaringD, CurreriPW. The role of platelet ag-gregation and release in fragment D-induced pul-monary dysfunction. Ann Surg1980;192:103–107.
99.
ManwaringD, CurreriPW. Platelet mediation of fragment D-induced respiratory distress syndrome. Surg Forum1981;31:242–243.
100.
ManwaringD, CurreriPW. Platelet and neutrophil sequestration after fragment D-induced respiratory distress. Circ Shock1982;9:75–80.
101.
OdomH, YorkFC, HillerFC, . Fibrin degra-dation product D in endotoxin shock. Microcirc1982;2(1):91–98.
102.
HopperKE, GeczyCL, DovierWA. A mechanism of migration inhibition in delayed-type hypersen-sitivity reactions. I. Fibrin deposition on the surfaces of alveolar macrophages in vivo. J Immunol1981;126:1052–1058.
103.
GeczyCL, HopperKE. A mechanism of migration inhibition in delayed-type hypersensitivity reac-tions. II. Lymphokines promote procoagulant activity of macrophages in vitro. J Immunol1981;126:105–116.
104.
HockingWG, GoldeDW. The pulmonary alveolar macrophage. N Engl J Med1979;301:639–645.
105.
RennardSL, CrystalRG. Fibronectin in human bronchopulmonary lavage fluid: Elevation in pa-tients with interstitial lung disease. J Clin Invest1981;69:113–122.
106.
ChapmanHAJr, VeurinZ, HibbsJBJr. Macro-phage fibrinolytic activity: Identification of two pathways of plasmin formation by intact cells and of a plasminogen activator inhibitor. Cell1982;28:653–662.
107.
SahaTM, JaffeE.Plasma fibronectin (opsonic gly-coprotein): H2 synthesis by vascular endothelial cells and role in cardiopulmonary integrity after trauma as related to reticuloendothelial function. Am J Med1980;68:577.
BachofenM, WeibelER. Structural alterations of lung parenchyma in the adult respiratory distress syndrome. In: BoneRC, editor. Adult respiratory dis-tress syndrome. Philadelphia: WB Saunders; 1982:35–56.
110.
TeplitzC.The case pathology and integrated medi-cal science of adult acute respiratory insufficiency. Surg Clin North Am1976;56:1091–1100.
111.
BachofenM, WeibelER. Alteration of the gas ex-change apparatus in adult respiratory insufficiency associated with septicemia. Am Rev Respir Dis1977;116:589–599.
112.
LamyM, FallatRJ, KoenigerE, . Pathological features and mechanisms of hypoxemia in adult res-piratory distress syndrome. Am Rev Respir Dis1976;114:267–277.